PDCD1 and neoplasm: To examine the anti-tumor efficacy of RCE, hPD-L1 knock-in MC38 tumor cells were injected subcutaneously (s.c.)into humanized PD-1 mice and RCE and anti-PD-1 were treated orally or intraperitoneally (i.p.)(Figure 2A).